(0.33%) 5 116.59 points
(0.33%) 38 365 points
(0.36%) 15 986 points
(-0.93%) $83.07
(5.56%) $2.03
(0.34%) $2 355.10
(0.46%) $27.66
(4.05%) $959.45
(-0.26%) $0.932
(-0.43%) $10.98
(-0.57%) $0.796
(1.69%) $93.43
@ $397.60
発行日: 30 4月 2024 @ 01:18
リターン: 0.07%
前回のシグナル: 4月 29 - 23:49
前回のシグナル:
リターン: 0.37 %
Live Chart Being Loaded With Signals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation...
Stats | |
---|---|
本日の出来高 | 241 272 |
平均出来高 | 1.20M |
時価総額 | 102.77B |
EPS | $0 ( 2024-02-05 ) |
次の収益日 | ( $4.10 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 28.69 |
ATR14 | $3.62 (0.91%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Sachs Bruce I | Buy | 109 | Deferred Stock Units |
2024-04-01 | Ambrose Kristen | Sell | 225 | Common Stock |
2024-04-02 | Ambrose Kristen | Sell | 240 | Common Stock |
2024-02-23 | Wagner Charles F Jr | Sell | 3 309 | Common Stock |
2024-02-23 | Tatsis Ourania | Sell | 3 309 | Common Stock |
INSIDER POWER |
---|
11.73 |
Last 100 transactions |
Buy: 259 544 | Sell: 201 703 |
ボリューム 相関
Vertex Pharmaceuticals 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Vertex Pharmaceuticals 相関 - 通貨/商品
Vertex Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $9.84B |
総利益: | $8.58B (87.17 %) |
EPS: | $14.05 |
FY | 2023 |
収益: | $9.84B |
総利益: | $8.58B (87.17 %) |
EPS: | $14.05 |
FY | 2022 |
収益: | $8.93B |
総利益: | $7.85B (87.90 %) |
EPS: | $12.97 |
FY | 2021 |
収益: | $7.57B |
総利益: | $6.67B (88.06 %) |
EPS: | $9.09 |
Financial Reports:
No articles found.
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。